STUDI INTERAKSI OBAT-OBAT JANTUNG YANG DILAKUKAN TERHADAP ORANG SEHAT: TINJAUAN SISTEMATIS

Yunita Sumartin; Elin Yulinah  Sukandar

doi:10.26874/kjif.v9i2.669

Penulis

Yunita Sumartin Program Studi Magister Farmasi, Fakultas Farmasi, Universitas Jenderal Achmad Yani, Cimahi, Indonesia
Elin Yulinah Sukandar Program Studi Magister Farmasi, Fakultas Farmasi, Universitas Jenderal Achmad Yani, Cimahi, Indonesia

DOI:

https://doi.org/10.26874/kjif.v9i2.669

Kata Kunci:

farmakodinamik, farmakokinetik, interaksi obat, kardiovaskular

Abstrak

Pasien dengan penyakit kardiovaskular memiliki prevalensi interaksi obat yang lebih tinggi dibandingkan kelompok pasien lain karena jumlah dan penggunaan obat yang komplek. Interaksi obat merupakan perubahan efek kerja dari suatu obat karena adanya obat lain ketika diberikan bersamaan. Jenis interaksi obat terdiri dari interaksi farmakokinetik, farmakodinamik, dan farmasetik. Studi ini berupa tinjauan sistematis yang bertujuan untuk mengidentifikasi interaksi obat yang berkaitan dengan obat-obat jantung. Proses penelusuran artikel dilakukan pada database PubMed dan ScienceDirect untuk mengidentifikasi semua artikel mengenai studi interaksi obat-obat jantung. Penelusuran artikel dibatasi pada tahun 2013 hingga 2023. Kata kunci yang digunakan dalam penelusuran artikel sebagai berikut: drug-drug interactions, cardiac patient, cardiac drug, cardiovascular drug, pharmacokinetics interaction, pharmacodynamic interaction dikombinasikan dengan boolean operator yaitu AND. Studi artikel yang telah memenuhi syarat, dimasukkan ke dalam penelitian untuk ditinjau. Jumlah keseluruhan artikel yang telah teridentifikasi dari database yang digunakan yaitu sebanyak 805 artikel, 7 artikel duplikasi dikeluarkan, 82 artikel tersedia teks lengkap, namun hanya 20 artikel sesuai dengan inklusi yang dilakukan review. Dari 20 artikel, 18 publikasi mengidentifikasi interaksi obat secara farmakokinetik, sedangkan interaksi secara farmakodinamik dilaporkan dalam 2 publikasi. Interaksi farmakokinetik banyak terjadi pada golongan obat Angiotensin II Reseptor Bloker (ARB). Selain itu terjadi pada golongan obat angiotensin receptor-neprilysin inhibitor (ARNI), calcium channel blocker, penghambat reseptor mineralkortikoid nonsteroid selektif, diuretik, beta-blocker, antikoagulan, dan antiplatelet. Interaksi farmakodinamik terjadi pada golongan obat calcium channel blocker dan beta-blocker. Untuk menghindari terjadinya interaksi obat, perlu pengetahuan mengenai mekanisme terjadinya interaksi obat dan efeknya terhadap pengobatan.

Kata kunci : Farmakodinamik, farmakokinetik, interaksi obat, kardiovaskular.

Abstract

Patients with cardiovascular diseases have a higher prevalence of drug interactions than other patient groups due to the number and complex use of drugs. Drug interactions are changes in the effect of a drug due to the presence of another drug when administered together. Types of drug interactions consist of pharmacokinetic, pharmacodynamic, and pharmaceutical interactions. This study is a systematic review that aims to identify drug interactions related to cardiac drugs. The article search process was conducted on PubMed and ScienceDirect databases to identify all articles on cardiac drug-drug interaction studies. Article searches were limited to the years 2013 to 2023. The keywords used in the article search were as follows: drug-drug interactions, cardiac patient, cardiac drug, cardiovascular drug, pharmacokinetics interaction, pharmacodynamic interaction combined with the boolean operator AND. Eligible study articles were included in the study for review. A total of 805 articles were identified from the database used, 7 duplicate articles were excluded, 82 articles were available in full text, however, only 20 articles that met the inclusion criteria were reviewed. Of the 20 articles, 18 publications identified pharmacokinetic drug interactions, while pharmacodynamic interactions were reported in 2 publications. Pharmacokinetic interactions mostly occurred in the Angiotensin II Receptor Blocker (ARB) drug class. In addition, angiotensin receptor-neprilysin inhibitors (ARNI), calcium channel blockers, selective nonsteroidal mineralocorticoid receptor blockers, diuretics, beta-blockers, anticoagulants, and antiplatelets were also reported. Pharmacodynamic interactions occur with calcium channel blockers and beta-blockers. To avoid drug interactions, it is necessary to know the mechanism of drug interactions and their effects on treatment.

Keywords: Pharmacodynamics, pharmacokinetics, drug Interactions, cardiovascular.

Referensi

Al-Jabi, S.W., Aldabe, L., Alhaj-Asaad, L., Thaher, M., Zyoud, S.H., and Sweileh, W.M., 2021. Assessment of drug interactions and their associated factors among patients with cardiovascular diseases: a cross-sectional study from the occupied Palestinian territory. Lancet (London, England), 398, S8.

Assefa, Y.A., Kedir, A., and Kahaliw, W., 2020. Survey on Polypharmacy and Drug-Drug Interactions Among Elderly People with Cardiovascular Diseases at Yekatit 12 Hospital, Addis Ababa, Ethiopia. Integrated Pharmacy Research and Practice, Volume 9, 1–9.

Ayalasomayajula, S., Schuehly, U., Pal, P., Chen, F., Zhou, W., Sunkara, G., and Langenickel, T.H., 2018. Effect of the angiotensin receptor–neprilysin inhibitor sacubitril/valsartan on the pharmacokinetics and pharmacodynamics of a single dose of furosemide. British Journal of Clinical Pharmacology, 84 (5), 926–936.

Delavenne, X., Magnin, M., Basset, T., Piot, M., Mallouk, N., Ressnikoff, D., Garcin, A., Laporte, S., Garnier, P., and Mismetti, P., 2013. Investigation of drug-drug interactions between clopidogrel and fluoxetine. Fundamental and Clinical Pharmacology, 27 (6), 683–689.

Frost, C.E., Byon, W., Song, Y., Wang, J., Schuster, A.E., Boyd, R.A., Zhang, D., Yu, Z., Dias, C., Shenker, A., and Lacreta, F., 2015. Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor. British Journal of Clinical Pharmacology, 79 (5), 838–846.

Gan, L., Jiang, X., Mendonza, A., Swan, T., Reynolds, C., Nguyen, J., Pal, P., Neelakantham, S., Dahlke, M., Langenickel, T., Rajman, I., Akahori, M., Zhou, W., Rebello, S., and Sunkara, G., 2016. Pharmacokinetic drug-drug interaction assessment of LCZ696 (an angiotensin receptor neprilysin inhibitor) with omeprazole, metformin or levonorgestrel-ethinyl estradiol in healthy subjects. Clinical Pharmacology in Drug Development, 5 (1), 27–39.

Gundlach, K., Wolf, K., Salem, I., Randerath, O., and Seiler, D., 2021. Safety of Candesartan, Amlodipine,

and Atorvastatin in Combination: Interaction Study in Healthy Subjects. Clinical Pharmacology in Drug Development, 10 (2), 190–197.

Hobl, E.L., Reiter, B., Schoergenhofer, C., Schwameis, M., Derhaschnig, U., Kubica, J., Stimpfl, T., and Jilma, B., 2016. Morphine decreases ticagrelor concentrations but not its antiplatelet effects: A randomized trial in healthy volunteers. European Journal of Clinical Investigation, 46 (1), 7–14.

Hobl, E.L., Stimpfl, T., Ebner, J., Schoergenhofer, C., Derhaschnig, U., Sunder-Plassmann, R., Jilma-Stohlawetz, P., Mannhalter, C., Posch, M., and Jilma, B., 2014. Morphine decreases clopidogrel concentrations and effects: A randomized, double-blind, placebo-controlled trial. Journal of the American College of Cardiology, 63 (7), 630–635.

Hunt, T.L., Tzanis, E., Bai, S., Manley, A., Chitra, S., and McGovern, P.C., 2021. The Effect of Verapamil, a P-gp Inhibitor, on the Pharmacokinetics, Safety, and Tolerability of Omadacycline in Healthy Adults: A Phase I, Open-Label, Single-Sequence Study. European Journal of Drug Metabolism and Pharmacokinetics, 46 (1), 85–92.

Jeddi, F.R., Nabovati, E., Peykani, F., Anvari, S., and Toolaroud, P.B., 2022. Potential Drug-Drug Interactions in a Cardiac Center: Development of Simple Software for Pattern Identification. Journal of Tehran University Heart Center, 17 (4), 215–222.

Kirigaya, Y., Shiramoto, M., Ishizuka, T., Uchimaru, H., Irie, S., Kato, M., Shimizu, T., Nakatsu, T., Nishikawa, Y., and Ishizuka, H., 2020. Pharmacokinetic interactions of esaxerenone with amlodipine and digoxin in healthy Japanese subjects. BMC Pharmacology and Toxicology, 21 (1), 1–10.

Lee, J., Lee, H., Jang, K., Lim, K.S., Shin, D., and Yu, K.S., 2014. Evaluation of the pharmacokinetic and pharmacodynamic drug interactions between cilnidipine and valsartan, in healthy volunteers. Drug Design, Development and Therapy, 8, 1781–1788.

Manitpisitkul, P., Curtin, C.R., Shalayda, K., Wang, S.S., Ford, L., and Heald, D., 2014. Pharmacokinetic interactions between topiramate and diltiazem, hydrochlorothiazide, or propranolol. Clinical Pharmacology in Drug Development, 3 (5), 378–387.

Moon, S.J., Jeon, J.Y., Jang, K., Yu, K.S., Lim, Y., and Kim, M.G., 2019. Pharmacokinetic interactions between telmisartan/ amlodipine and rosuvastatin after multiple oral administrations in healthy Korean male subjects. Drug Design, Development and Therapy, 13, 2533–2542.

Moon, S.J., Jeon, J.Y., Yu, K.S., and Kim, M.G., 2019. Pharmacokinetic Interaction Among Telmisartan, Amlodipine, and Hydrochlorothiazide After a Single Oral Administration in Healthy Male Subjects. Clinical Therapeutics, 41 (11), 2273–2282.

Prastiya, U. and Maulani, D., 2022. Potensi Interaksi Obat Bisoprolol Pada Pasien BPJS Rawat Jalan di Poli Jantung Rumah Sakit Al-Huda Banyuwangi (Periode Januari-Maret 2022), 5 (No.2), 64–71.

Roh, H., Son, H., Lee, D., Chang, H., Yun, C., and Park, K., 2014. Pharmacokinetic interaction between rosuvastatin and olmesartan: A randomized, open-label, 3-period, multiple-dose crossover study in healthy Korean male subjects. Clinical Therapeutics, 36 (8), 1159–1170.

Seong, S.J., Ohk, B., Kang, W.Y., Gwon, M.R., Kim, B.K., Cho, S., Yang, D.H., Lee, H.W., and Yoon, Y.R., 2019. Pharmacokinetic Drug Interactions Between Amlodipine, Valsartan, and Rosuvastatin in Healthy Volunteers. Advances in Therapy, 36 (7), 1642–1656.

Sharma, S., Chhetri, H.P., and Alam, K., 2014. A study of potential drug-drug interactions among hospitalized cardiac patients in a teaching hospital in Western Nepal. Indian Journal of Pharmacology, 46 (2), 152–156.

Son, M., Guk, J., Kim, Y., Woo Chae, D., Heo, Y.A., Soh, D., and Park, K., 2016. Pharmacokinetic Interaction Between Rosuvastatin, Telmisartan, and Amlodipine in Healthy Male Korean Subjects: A Randomized, Open-label, Multiple-dose, 2-period Crossover Study. Clinical Therapeutics, 38 (8), 1845–1857.

Teng, R., Kujacic, M., and Hsia, J., 2014. Pharmacokinetic interaction study of ticagrelor and cyclosporine in healthy volunteers. Clinical Drug Investigation, 34 (8), 529–536.

Tsai, M., Case, M., Ardayfio, P., Hochstetler, H., and Wilbraham, D., 2020. Effects of Lasmiditan on Cardiovascular Parameters and Pharmacokinetics in Healthy Subjects Receiving Oral Doses of Propranolol. Clinical Pharmacology in Drug Development, 9 (5), 629–638.

Wen, J., Zeng, M., Liu, Z., Zhou, H., Xu, H., Huang, M., and Zhang, W., 2019. The influence of telmisartan on metformin pharmacokinetics and pharmacodynamics. Journal of Pharmacological Sciences, 139 (1), 37–41.

Yang, B.B., Gillespie, B., Smith, B., Smith, W., Lissmats, A., Rudebeck, M., Kullenberg, T., and Olsson, B., 2015. Pharmacokinetic and pharmacodynamic interactions between palifermin and heparin. Journal of Clinical Pharmacology, 55 (10), 1109–1118.